Annual EBIT
-$6.05 M
-$26.39 M-129.73%
31 December 2023
Summary:
Pharming Group NV annual earnings before interest & taxes is currently -$6.05 million, with the most recent change of -$26.39 million (-129.73%) on 31 December 2023. During the last 3 years, it has fallen by -$56.09 million (-112.09%). PHAR annual EBIT is now -109.21% below its all-time high of $71.46 million.PHAR EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly EBIT
$4.51 M
+$2.60 M+135.74%
30 September 2024
Summary:
Pharming Group NV quarterly earnings before interest & taxes is currently $4.51 million, with the most recent change of +$2.60 million (+135.74%) on 30 September 2024. Over the past year, it has increased by +$2.60 million (+136.48%). PHAR quarterly EBIT is now -87.31% below its all-time high of $35.55 million, reached on 30 September 2017.PHAR Quarterly EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM EBIT
-$9.33 M
+$2.60 M+21.82%
30 September 2024
Summary:
Pharming Group NV TTM earnings before interest & taxes is currently -$9.33 million, with the most recent change of +$2.60 million (+21.82%) on 30 September 2024. Over the past year, it has increased by +$15.78 million (+62.85%). PHAR TTM EBIT is now -111.82% below its all-time high of $78.90 million, reached on 30 September 2020.PHAR TTM EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
PHAR EBIT Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -129.7% | +136.5% | +62.9% |
| 3 y3 years | -112.1% | +70.8% | -163.3% |
| 5 y5 years | -134.9% | -76.5% | -131.1% |
PHAR EBIT High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -112.1% | at low | -78.4% | +127.0% | -123.1% | +62.9% |
| 5 y | 5 years | -109.2% | at low | -80.6% | +127.0% | -111.8% | +62.9% |
| alltime | all time | -109.2% | +92.5% | -87.3% | +104.7% | -111.8% | +88.4% |
Pharming Group NV EBIT History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $4.51 M(+135.7%) | -$9.33 M(-21.8%) |
| June 2024 | - | $1.91 M(-112.7%) | -$11.93 M(+16.0%) |
| Mar 2024 | - | -$15.07 M(+2090.1%) | -$10.29 M(+13.1%) |
| Dec 2023 | -$6.05 M(-129.7%) | -$688.00 K(-136.1%) | -$9.10 M(-63.8%) |
| Sept 2023 | - | $1.91 M(-46.4%) | -$25.11 M(+52.3%) |
| June 2023 | - | $3.56 M(-125.7%) | -$16.49 M(-2031.3%) |
| Mar 2023 | - | -$13.88 M(-16.9%) | $854.00 K(-95.8%) |
| Dec 2022 | $20.34 M(-30.3%) | -$16.70 M(-258.6%) | $20.34 M(-49.6%) |
| Sept 2022 | - | $10.53 M(-49.6%) | $40.41 M(+24.3%) |
| June 2022 | - | $20.91 M(+272.5%) | $32.52 M(+59.5%) |
| Mar 2022 | - | $5.61 M(+67.1%) | $20.39 M(-30.1%) |
| Dec 2021 | $29.17 M(-41.7%) | $3.36 M(+27.1%) | $29.17 M(+97.9%) |
| Sept 2021 | - | $2.64 M(-69.9%) | $14.74 M(-58.3%) |
| June 2021 | - | $8.78 M(-39.0%) | $35.38 M(-16.6%) |
| Mar 2021 | - | $14.39 M(-229.9%) | $42.42 M(-15.2%) |
| Dec 2020 | $50.04 M(-23.8%) | -$11.07 M(-147.6%) | $50.04 M(-36.6%) |
| Sept 2020 | - | $23.28 M(+47.1%) | $78.90 M(+5.5%) |
| June 2020 | - | $15.83 M(-28.1%) | $74.81 M(+1.4%) |
| Mar 2020 | - | $22.00 M(+23.7%) | $73.75 M(+12.3%) |
| Dec 2019 | $65.66 M(+278.4%) | $17.79 M(-7.3%) | $65.66 M(+118.9%) |
| Sept 2019 | - | $19.19 M(+30.0%) | $30.00 M(+8.0%) |
| June 2019 | - | $14.76 M(+6.1%) | $27.77 M(+31.3%) |
| Mar 2019 | - | $13.92 M(-177.9%) | $21.15 M(+21.9%) |
| Dec 2018 | $17.35 M(-121.6%) | -$17.87 M(-205.3%) | $17.35 M(-128.8%) |
| Sept 2018 | - | $16.96 M(+108.5%) | -$60.15 M(+44.7%) |
| June 2018 | - | $8.14 M(-19.6%) | -$41.56 M(-44.2%) |
| Mar 2018 | - | $10.12 M(-110.6%) | -$74.45 M(-7.4%) |
| Dec 2017 | -$80.43 M(+448.2%) | -$95.37 M(-368.2%) | -$80.43 M(-844.5%) |
| Sept 2017 | - | $35.55 M(-243.7%) | $10.80 M(-137.4%) |
| June 2017 | - | -$24.75 M(-698.1%) | -$28.90 M(+316.4%) |
| Mar 2017 | - | $4.14 M(-200.0%) | -$6.94 M(-52.7%) |
| Dec 2016 | -$14.67 M | -$4.14 M(-0.2%) | -$14.67 M(+43.4%) |
| Sept 2016 | - | -$4.15 M(+48.5%) | -$10.23 M(+7.8%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2016 | - | -$2.79 M(-22.3%) | -$9.49 M(-6.9%) |
| Mar 2016 | - | -$3.59 M(-1287.6%) | -$10.20 M(+3.0%) |
| Dec 2015 | -$9.90 M(+45.7%) | $302.50 K(-108.9%) | -$9.90 M(+108.7%) |
| Sept 2015 | - | -$3.41 M(-2.7%) | -$4.75 M(-23.6%) |
| June 2015 | - | -$3.50 M(+6.1%) | -$6.21 M(+5.3%) |
| Mar 2015 | - | -$3.30 M(-160.4%) | -$5.89 M(-13.3%) |
| Dec 2014 | -$6.80 M(-57.9%) | $5.46 M(-212.2%) | -$6.80 M(-71.9%) |
| Sept 2014 | - | -$4.87 M(+52.8%) | -$24.22 M(+5.1%) |
| June 2014 | - | -$3.19 M(-24.2%) | -$23.05 M(+26.4%) |
| Mar 2014 | - | -$4.20 M(-64.8%) | -$18.24 M(+13.0%) |
| Dec 2013 | -$16.13 M(-43.3%) | -$11.96 M(+223.7%) | -$16.13 M(+49.0%) |
| Sept 2013 | - | -$3.69 M(-328.1%) | -$10.83 M(-24.9%) |
| June 2013 | - | $1.62 M(-177.2%) | -$14.41 M(-41.9%) |
| Mar 2013 | - | -$2.10 M(-68.5%) | -$24.78 M(-12.8%) |
| Dec 2012 | -$28.43 M(+24.4%) | -$6.66 M(-8.5%) | -$28.43 M(+7.5%) |
| Sept 2012 | - | -$7.28 M(-16.9%) | -$26.44 M(+7.4%) |
| June 2012 | - | -$8.75 M(+52.4%) | -$24.63 M(+9.3%) |
| Mar 2012 | - | -$5.75 M(+23.1%) | -$22.53 M(-1.4%) |
| Dec 2011 | -$22.85 M(-53.3%) | -$4.67 M(-14.6%) | -$22.85 M(-52.0%) |
| Sept 2011 | - | -$5.47 M(-17.9%) | -$47.64 M(-6.7%) |
| June 2011 | - | -$6.65 M(+9.7%) | -$51.08 M(+2.2%) |
| Mar 2011 | - | -$6.06 M(-79.4%) | -$49.99 M(-1.2%) |
| Dec 2010 | -$48.95 M(+45.7%) | -$29.45 M(+230.5%) | -$50.61 M(+69.5%) |
| Sept 2010 | - | -$8.91 M(+60.3%) | -$29.85 M(-0.3%) |
| June 2010 | - | -$5.56 M(-16.8%) | -$29.94 M(-3.5%) |
| Mar 2010 | - | -$6.68 M(-23.2%) | -$31.03 M(-5.7%) |
| Dec 2009 | -$33.58 M(+44.5%) | -$8.70 M(-3.3%) | -$32.92 M(+35.9%) |
| Sept 2009 | - | -$9.00 M(+35.3%) | -$24.22 M(+59.2%) |
| June 2009 | - | -$6.65 M(-22.4%) | -$15.22 M(+77.6%) |
| Mar 2009 | - | -$8.57 M | -$8.57 M |
| Dec 2008 | -$23.25 M(-22.2%) | - | - |
| Dec 2007 | -$29.86 M(+31.2%) | - | - |
| Dec 2006 | -$22.77 M(+11.9%) | - | - |
| Dec 2005 | -$20.35 M | - | - |
FAQ
- What is Pharming Group NV annual earnings before interest & taxes?
- What is the all time high annual EBIT for Pharming Group NV?
- What is Pharming Group NV annual EBIT year-on-year change?
- What is Pharming Group NV quarterly earnings before interest & taxes?
- What is the all time high quarterly EBIT for Pharming Group NV?
- What is Pharming Group NV quarterly EBIT year-on-year change?
- What is Pharming Group NV TTM earnings before interest & taxes?
- What is the all time high TTM EBIT for Pharming Group NV?
- What is Pharming Group NV TTM EBIT year-on-year change?
What is Pharming Group NV annual earnings before interest & taxes?
The current annual EBIT of PHAR is -$6.05 M
What is the all time high annual EBIT for Pharming Group NV?
Pharming Group NV all-time high annual earnings before interest & taxes is $71.46 M
What is Pharming Group NV annual EBIT year-on-year change?
Over the past year, PHAR annual earnings before interest & taxes has changed by -$26.39 M (-129.73%)
What is Pharming Group NV quarterly earnings before interest & taxes?
The current quarterly EBIT of PHAR is $4.51 M
What is the all time high quarterly EBIT for Pharming Group NV?
Pharming Group NV all-time high quarterly earnings before interest & taxes is $35.55 M
What is Pharming Group NV quarterly EBIT year-on-year change?
Over the past year, PHAR quarterly earnings before interest & taxes has changed by +$2.60 M (+136.48%)
What is Pharming Group NV TTM earnings before interest & taxes?
The current TTM EBIT of PHAR is -$9.33 M
What is the all time high TTM EBIT for Pharming Group NV?
Pharming Group NV all-time high TTM earnings before interest & taxes is $78.90 M
What is Pharming Group NV TTM EBIT year-on-year change?
Over the past year, PHAR TTM earnings before interest & taxes has changed by +$15.78 M (+62.85%)